Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep 17:2020:4956946.
doi: 10.1155/2020/4956946. eCollection 2020.

Antibody-Based Immunotherapeutic Strategies for the Treatment of Hematological Malignancies

Yizhao Han  1   2 , Zhuojun Liu  1   2 , Jia Liu  1   2 , Weiqi Yan  1   2 , Yuanshi Xia  2 , Shuhua Yue  2 , Jian Yu  1   2
Affiliations
Review

Antibody-Based Immunotherapeutic Strategies for the Treatment of Hematological Malignancies

Yizhao Han et al. Biomed Res Int. .

Abstract

As the most common type of cancer in the world, hematological malignancies (HM) account for 10% of all annual cancer deaths and have attracted more attention. Conventional treatments, such as chemotherapy, radiotherapy, and hematopoietic stem cell transplantation (HSCT), could relieve patients suffering HM. However, serious side effects and high costs bring patients both physical complaints and mental pressure. Recently, compared with conventional therapeutic strategies for HM patients, antibody-based immunotherapies, including cancer vaccines, oncolytic virus therapies, monoclonal antibody treatments, and CAR-T cell therapies, have displayed longer survival time and fewer adverse reactions, even though specific efficacy and safety of these antibody-based immunotherapies still need to be evaluated and improved. This review summarized the advantages of antibody-based immunotherapies over conventional treatments, as well as its existing difficulties and solutions, thereby enhancing the understanding and applications of antibody-based immunotherapies in HM treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no conflict of interest regarding the publication of this paper.

Figures

Figure 1
Figure 1
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Siegel R. L., Miller K. D., Jemal A. Cancer statistics, 2019. CA: a Cancer Journal for Clinicians. 2019;69(1):7–34. doi: 10.3322/caac.21551. - DOI - PubMed
    1. Eppert K., Takenaka K., Lechman E. R., et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nature Medicine. 2011;17(9):1086–1093. doi: 10.1038/nm.2415. - DOI - PubMed
    1. Kotb M. G., Soliman A. E. R., Ibrahim R. I., Said R. M. M., el Din M. M. W. Chemotherapy-induced cognitive impairment in hematological malignancies. The Egyptian Journal of Neurology, Psychiatry and Neurosurgery. 2019;55(1):1–8. doi: 10.1186/s41983-019-0104-9. - DOI
    1. Zeng Q. Z., Zhang Y. Y., Wu Y. J., et al. Frequency, risk factors, and outcome of active tuberculosis following allogeneic hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation. 2020;26(6):1203–1209. doi: 10.1016/j.bbmt.2020.02.018. - DOI - PubMed
    1. Taefehshokr N., Baradaran B., Baghbanzadeh A., Taefehshokr S. Promising approaches in cancer immunotherapy. Immunobiology. 2020;225(2, article 151875) doi: 10.1016/j.imbio.2019.11.010. - DOI - PubMed